ImmunityBio Inc. (IBRX)
NASDAQ: IBRX
· Real-Time Price · USD
2.39
0.02 (0.84%)
At close: Sep 04, 2025, 3:59 PM
2.38
-0.42%
Pre-market: Sep 05, 2025, 06:06 AM EDT
0.84% (1D)
| Bid | 2.36 |
| Market Cap | 2.26B |
| Revenue (ttm) | 56.6M |
| Net Income (ttm) | -367.09M |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -4.98 |
| Forward PE | -6.77 |
| Analyst | Buy |
| Ask | 2.41 |
| Volume | 6,305,050 |
| Avg. Volume (20D) | 8,724,982 |
| Open | 2.38 |
| Previous Close | 2.37 |
| Day's Range | 2.29 - 2.40 |
| 52-Week Range | 1.83 - 7.48 |
| Beta | -0.07 |
About IBRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
ImmunityBio Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+5.78%
ImmunityBio shares are trading higher after the co...
Unlock content with
Pro Subscription
2 weeks ago
-0.88%
IBRX stock has given up its prior gain. ImmunityBio shares were trading higher after the company announced it has opened a new Phase 2 study to assess the BioShield platform.
2 weeks ago · businesswire.com
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVIDCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored ...
1 month ago · seekingalpha.com
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva ApprovalRecent ASCO data and UK MHRA approval for ANKTIVA reinforce my bullish thesis, despite the FDA's Refusal to File setback. ANKTIVA's potential to reverse lymphopenia in late-stage cancer patients could...